Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $1,225,585,000 across 7 holdings for the quarter ended 2020-09-30, in a 13F-HR filed 2020-11-04.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-010814
- Period
- 2020-09-30
- Reported value
- $1.23B
- Holdings
- 7
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Stakes and trades reported after 2020-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NRIXnew | +6,755,881 | $236M |
| NGM BIOPHARMACEUTICALS INCadded | +310,954 | $4.95M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RCUSexited | -1,767,676 | -$43.7M |
| RAPT THERAPEUTICS INCreduced | -1,146,654 | -$36.9M |
| GRITSTONE BIO INCreduced | -831,452 | -$2.2M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2020
Share positions as resolved from 13F-HR 0000950123-20-010814, largest first. % of portfolio is the value over $1,225,585,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 18,017,932 | $287M | 23.39% | +310,954 | |||
| RVMDREVOLUTION MEDICINES INC | 7,977,384 | $278M | 22.65% | 0 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 6,755,881 | $236M | 19.24% | new | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 5,630,497 | $181M | 14.79% | -1,146,654 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 6,051,376 | $123M | 10% | 0 | |||
| ORICORIC PHARMACEUTICALS INC | 4,768,181 | $119M | 9.73% | 0 | Timeline | ||
| GRITSTONE BIO INCGRITSTONE BIO INC | 869,493 | $2.3M | 0.19% | -831,452 |
Sold out in Q3 2020
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| RCUSARCUS BIOSCIENCES INC | 1,767,676 | $43.7M | shares |
How Q3 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-20-010814 | base | 2020-11-04 | acceptance time not in the bulk data set |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13D/A 0001193125-26-467393 | SRZN | 2026-11-18 | ||
| 13D/A 0001193125-26-463722 | TNYA | 2026-11-16 | ||
| 13D/A 0001193125-26-451852 | SRZN | 2026-11-06 | ||
| Form 4 0001193125-26-429058 | Surrozen, Inc./DE | 2026-10-22 | ||
| 13D/A 0001193125-26-429027 | SRZN | 2026-10-22 | ||
| 13F-HR 0000950123-20-010814 | Quarter ended 2020-09-30 | 2020-11-04 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-20-008388 | Quarter ended 2020-06-30 | 2020-08-12 | acceptance time not in the bulk data set | |
| 13F-HR 0001606074-20-000005 | Quarter ended 2020-03-31 | 2020-05-07 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-20-001647 | Quarter ended 2019-12-31 | 2020-02-12 | acceptance time not in the bulk data set | |
| 13F-HR 0000903514-19-000008 | Quarter ended 2019-09-30 | 2019-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001600420-19-000007 | Quarter ended 2019-06-30 | 2019-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001606074-19-000002 | Quarter ended 2019-03-31 | 2019-05-08 | acceptance time not in the bulk data set | |
| 13F-HR 0001606074-19-000001 | Quarter ended 2018-12-31 | 2019-02-13 | acceptance time not in the bulk data set | |
| 13F-NT 0001606074-15-000005 | Quarter ended 2015-09-30 | 2015-11-06 | acceptance time not in the bulk data set | |
| 13F-NT 0001606074-15-000004 | Quarter ended 2015-06-30 | 2015-08-06 | acceptance time not in the bulk data set | |
| 13F-NT 0001606074-15-000003 | Quarter ended 2015-03-31 | 2015-04-23 | acceptance time not in the bulk data set | |
| 13F-NT 0001606074-15-000001 | Quarter ended 2014-12-31 | 2015-02-05 | acceptance time not in the bulk data set |